June 10, 2020
Valerie Guild headshot

Remembering Valerie Guild, a tireless advocate for patients with melanoma

Valerie Guild was Founder and President of the non-profit organization AIM at Melanoma, and served as a patient advocate on ECOG-ACRIN’s Melanoma Committee for over ten years.
June 9, 2020
Pills on scale

Cancer treatment de-escalation: improving cancer care by tailoring treatment

De-escalation is an effort to reduce the intensity of treatment without sacrificing efficacy. This issue covers several de-escalation trials: DECREASE, CompassHER2 pCR, and E3311.
June 8, 2020

Now Enrolling: The DECREASE trial seeks to decrease treatment side effects – and improve quality of life – for people with early-stage anal cancer

This study is evaluating whether lower doses of chemoradiation will be able to effectively treat early-stage anal squamous cell carcinoma while also decreasing side effects.
June 7, 2020

Now Enrolling: The CompassHER2 pCR trial is determining if certain patients with early-stage HER2 positive breast cancer may benefit from reduced chemotherapy

The purpose of this study is to find out if some patients with early-stage HER2 positive breast cancer can safely be treated with less chemotherapy than is generally used.
June 6, 2020

Ongoing Trial: EA3161 is testing maintenance immunotherapy versus observation in patients with HPV-related throat cancer

This trial is comparing chemotherapy and radiation to chemotherapy and radiation plus an immunotherapy drug.
June 6, 2020
Oropharynx image

Trial Results: ECOG-ACRIN plans to conduct a randomized phase 3 trial aimed at sparing people with oropharynx cancer unnecessary side effects from treatment, based on the recent results of phase 2 study E3311

This study showed that surgery followed by low-dose radiation alone led to very good outcomes, similar to surgery with standard-dose radiation, preserving patients’ throat function and potentially sparing them unnecessary side effects.